Session 6: Insights from Health Care Systems on Bispecifics: Patient Treatment, Monitoring and Transition of Care

home / training-academy / insights-from-healthcare-systems-and-bispecifics-patient-treatment-monitoring-and-transition-of

Binod Dhakal, MD, MS, and a panel of experts in multiple myeloma provide a look at an upcoming Cancer Network Training Academy program discussing how to incorporate bispecific antibodies in the treatment of multiple myeloma, and how healthcare systems implement step-up dosing, treatment doses and transition of care. The panel also offers insights into the recommended strategies for monitoring patients receiving treatment with bispecifics.

Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)

EP. 1: Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
May 31st 2023

Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.

Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment

EP. 2: Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD
May 31st 2023

Dr Cindy Varga discusses recent data on the FDA-approved agent teclistamab, a bispecific antibody for patients with relapsed/refractory multiple myeloma.